Evidence mapPaperPMID 27873225Full record

SynthesisPharmacoEconomics2017

How Consistent is the Relationship between Improved Glucose Control and Modelled Health Outcomes for People with Type 2 Diabetes Mellitus? a Systematic Review.

Xinyang Hua, Thomas Wai-Chun Lung, Andrew Palmer, Lei Si, William H Herman, Philip Clarke

Open access · hybridAbstract readSystematic Review
In one paragraph

Synthesis in PharmacoEconomics, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
8.8field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 20 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 2 countries.

Xinyang HuaSchool of Population and Global Health, University of Melbourne, Level 4, 207 Bouverie Street, Carlton, VIC, 3053, Australia.
Thomas Wai-Chun LungSchool of Population and Global Health, University of Melbourne, Level 4, 207 Bouverie Street, Carlton, VIC, 3053, Australia.
Andrew PalmerMenzies Research Institute, University of Tasmania, Hobart, TAS, Australia.
Lei SiMenzies Research Institute, University of Tasmania, Hobart, TAS, Australia.
William H HermanSchool of Public Health, University of Michigan, Ann Arbor, MI, USA.
Philip ClarkeSchool of Population and Global Health, University of Melbourne, Level 4, 207 Bouverie Street, Carlton, VIC, 3053, Australia. philip.clarke@unimelb.edu.au.
University of Melbourne · AUUniversity of Tasmania · AUUniversity of Michigan–Ann Arbor · US

Funding

Pilot and Feasibility ProgramP30DK092926 · UNIVERSITY OF MICHIGAN AT ANN ARBOR · 2025 to 2025
$779k
NIDDK NIH HHS P30 DK092926
6 · The paper itself

Abstract

backgroundThere are an increasing number of studies using simulation models to conduct cost-effectiveness analyses for type 2 diabetes mellitus.

objectiveTo evaluate the relationship between improvements in glycosylated haemoglobin (HbA

methodsA systematic review was conducted on MEDLINE and EMBASE to collect cost-effectiveness studies using type 2 diabetes simulation models that reported modelled health outcomes of blood glucose-related interventions in terms of quality-adjusted life-years (QALYs) or life expectancy (LE). The data extracted included information used to characterise the study cohort, the intervention's treatment effects on risk factors and model outcomes. Linear regressions were used to test the relationship between the difference in HbA

resultsSeventy-six studies were included in this research, contributing to 124 pair of comparators. The pooled regressions indicated that the marginal effect of a 1% HbA

conclusionThere is a consistent relationship between ∆HbA

Indexed as

Models, EconomicBlood GlucoseComputer SimulationCost-Benefit AnalysisDiabetes Mellitus, Type 2Glycated HemoglobinHumansHypoglycemic AgentsLinear ModelsQuality-Adjusted Life YearsRisk FactorsBlood GlucoseGlycated HemoglobinHypoglycemic Agents

Identifiers

PMID27873225
PMCPMC5306373
OpenAlexW2553216067

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.